JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $71 Price Target
JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:CYTK) with a Market Outperform and maintains $71 price target.
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle
Cytokinetics Incorporated (NASDAQ:CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At…
Needham Maintains Buy on Cytokinetics, Raises Price Target to $60
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $58 to $60.
FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate
The FDA issued a Complete Response Letter to Cytokinetics Incorporated’s (NASDAQ:CYTK) omecamtiv mecarbil, an investigational, selective, small molecule cardiac myosin activator, for…
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Needham Reiterates Buy on Cytokinetics, Maintains $58 Price Target
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $58 price target.
B of A Securities Initiates Coverage On Cytokinetics with Neutral Rating, Announces Price Target of $49
B of A Securities analyst Jason Zemansky initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Neutral rating and announces Price Target of $49.
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
Goldman Sachs Maintains Buy on Cytokinetics, Raises Price Target to $56
Goldman Sachs analyst Madhu Kumar maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $47 to $56.
Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.